Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Virginia Garrison"'
Autor:
Jimena Trillo-Tinoco, Om Prakash, Shanta Chawla, Hillary Dinh, Virginia Garrison, Luis Del Valle, Katie Nguyen, Scott Wieland, Adriana Zapata, Thomas Reske, Bradley Spieler, Jim Outland, Daniel J. Levitt, Karlie Plaisance-Bonstaff, Chris Parsons, Mary Meyaski-Schluter, Erin Meyaski
Publikováno v:
Journal of Clinical Oncology. 34:11038-11038
11038Background: In the past Kaposi's sarcoma (KS) was a major cause of morbidity and mortality in HIV-infected individuals. Risk factors are defined by the TIS scoring system (tumor extent, immune...
Autor:
William D. Rooney, Jesus Lovera, Virginia Garrison, Dennis Bourdette, Dennis R. Koop, Alexander B. Ramos
Publikováno v:
Neurology. 78:P03.050-P03.050
Objective: Assess the safety of Polyphenon E in subjects with multiple sclerosis (MS) and determine whether Polyphenon E would be futile as a neuroprotective agent. Background Polyphenon E (Mitsui Norin; Shizuoka, Japan) is an extract from the leaves
Publikováno v:
American Scientist. 90:228
Autor:
Virginia Garrison, Kevin Railey
Publikováno v:
Browning Institute Studies. 16:181-193
Autor:
Kevin Railey, Virginia Garrison
Publikováno v:
Browning Institute Studies. 15:177-189
BIS Browning Institute Studies BSN Browning Society Notes DAI Dissertation Abstracts International SBHC Studies in Browning and His Circle TLS Times Literary Supplement VP Victorian Poetry VS Victorian Studies Y WES The Year's Work in English Studies
Publikováno v:
Browning Institute Studies. 13:201-212
SBHC Studies in Browning and His Circle TLS Times Literary Supplement VP Victorian Poetry VS Victorian Studies YWES The Year's Work in English Studies An asterisk indicates that we have not seen the item or have seen only a clipping. Readers are enco
Autor:
Deidre J. Devier, Anne L. Foundas, William D. Rooney, Virginia Garrison, Blake Kovner, Tara Reza, Dennis Bourdette, Dennis R. Koop, Jesus Lovera, Alexander B. Ramos
Publikováno v:
Journal of the Neurological Sciences. (1-2):46-52
ObjectivesPhase I (PhI): assess the safety of Polyphenon E in people with multiple sclerosis (MS) and determine the futility of Polyphenon E as a neuroprotective agent. Correlate plasma levels of EGCG with neuroprotective effects.Phase II (PhII): Fur